U.S., Aug. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07791498) titled 'Teclistamab In Waldenstrom's Macroglobulinemia' on Aug. 24.
Brief Summary: The goal of this clinical trial is to assess the efficacy of teclistamab in participants with relapsed or refractory Waldenstrom's macroglobulinemia who have received prior therapy. This study also aims to assess the safety and tolerability of teclistamab, how quickly and to what extent response is seen in participants, how strong any clinical benefit of teclistamab might be, and determine the response to teclistamab based on the combination of MY88 and CXCR4 mutations. The main questions it aims to answer are:
* Will teclistamab be effective in treating Wal...